Lif: Strong momentum for ATMP in Denmark
Danish patients with serious illnesses are increasingly gaining access to advanced therapy medicinal products (ATMPs). This is shown by a new report from the Danish Medicines Council, which arouses optimism at Danish pharma trade group Lif and underlines the great potential for the future.
The Danish Medicines Council has just announced that it has recommended 75% of the ATMP medicines it has assessed. The Lif says it has worked hard to ensure that this happens, and it is therefore extremely positive because it ensures patients have access to new, innovative treatments.
According to a recent analysis by the Lif, ATMPs and indications points to the same development: It shows that in February 2025 there are 21 ATMP drugs with a valid European Medicines Agency (EMA) marketing authorization, which together cover 28 different disease areas (indications).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze